Toll Free: 1-888-928-9744

Osteoarthritis Pain - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 202 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Osteoarthritis Pain - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Pipeline Review, H1 2017, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. It may be diagnosed by physical examination and MRI and X-ray imaging. The condition may be controlled by weight control, exercise and medication. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 22, 5, 1, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Osteoarthritis Pain - Overview 8 Osteoarthritis Pain - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 19 Osteoarthritis Pain - Therapeutics Assessment 20 Assessment by Target 20 Assessment by Mechanism of Action 23 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Osteoarthritis Pain - Companies Involved in Therapeutics Development 30 AbbVie Inc 30 Addex Therapeutics Ltd 30 Allergan Plc 31 Ampio Pharmaceuticals Inc 31 Antibe Therapeutics Inc 32 Aralez Pharmaceuticals Inc 32 Arena Pharmaceuticals Inc 33 Array BioPharma Inc 33 Astellas Pharma Inc 34 Axsome Therapeutics Inc 34 BELLUS Health Inc 35 Boehringer Ingelheim GmbH 35 Cara Therapeutics Inc 36 Chromocell Corp 36 Eli Lilly and Company 37 Elite Pharmaceuticals Inc 37 Eupraxia Pharmaceuticals Inc 38 Flexion Therapeutics Inc 38 Genzyme Corp 39 GlaxoSmithKline Plc 39 Grunenthal GmbH 40 Iroko Pharmaceuticals LLC 40 Marina Biotech Inc 41 Medestea Research & Production SpA 41 MedImmune LLC 42 Merck & Co Inc 42 Nuvo Pharmaceuticals Inc 43 Ono Pharmaceutical Co Ltd 43 Pfizer Inc 44 Phosphagenics Ltd 44 ProteoThera Inc 45 pSivida Corp 45 Purdue Pharma LP 46 Regeneron Pharmaceuticals Inc 46 Rottapharm Biotech Srl 47 Shionogi & Co Ltd 47 Symic Biomedical Inc 48 Taiwan Liposome Company Ltd 48 Vertex Pharmaceuticals Inc 49 Zynerba Pharmaceuticals Inc 49 Osteoarthritis Pain - Drug Profiles 50 (amlodipine besylate + celecoxib) - Drug Profile 50 (celecoxib + lisinopril) - Drug Profile 54 (celecoxib + olmesartan) - Drug Profile 55 (lidocaine hydrochloride + tetracaine) - Drug Profile 56 (naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile 58 2-CCPA - Drug Profile 60 AAT-008 - Drug Profile 61 ADX-71441 - Drug Profile 62 AF-219 - Drug Profile 66 Ampion - Drug Profile 70 APD-371 - Drug Profile 79 AQU-010 - Drug Profile 80 ARRY-954 - Drug Profile 81 AS-288640100 - Drug Profile 82 ASP-7962 - Drug Profile 83 ATB-346 - Drug Profile 84 BI-1026706 - Drug Profile 89 BLU-5937 - Drug Profile 91 cannabidiol - Drug Profile 92 capsaicin - Drug Profile 97 CC-8464 - Drug Profile 100 cebranopadol - Drug Profile 102 celecoxib - Drug Profile 105 CR-4056 - Drug Profile 106 CRB-0089 - Drug Profile 108 dapansutrile - Drug Profile 109 dexamethasone SR - Drug Profile 110 difelikefalin - Drug Profile 111 duloxetine hydrochloride DR - Drug Profile 120 ELS-130 - Drug Profile 123 fasinumab - Drug Profile 124 fluticasone propionate ER - Drug Profile 127 grapiprant - Drug Profile 128 GSK-3196165 - Drug Profile 130 GZ-389988 - Drug Profile 133 ibuprofen - Drug Profile 134 MEDI-7352 - Drug Profile 135 naproxen sodium - Drug Profile 136 NEO-6860 - Drug Profile 138 OLP-1002 - Drug Profile 139 onabotulinumtoxinA - Drug Profile 140 ONO-4474 - Drug Profile 145 oxycodone ER - Drug Profile 146 PA-300 DR - Drug Profile 149 PA-65020 - Drug Profile 150 PRT-1000 - Drug Profile 152 S-120083 - Drug Profile 153 SB-061 - Drug Profile 154 Small Molecules for Osteoarthritis Pain - Drug Profile 156 Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain - Drug Profile 157 Small Molecules to Block Nav1.7 for Osteoarthritis Pain - Drug Profile 158 Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 159 Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile 160 Small Molecules to Inhibit PDE2 for Osteoarthritis Pain - Drug Profile 161 tanezumab - Drug Profile 162 TLC-599 - Drug Profile 166 triamcinolone acetonide ER - Drug Profile 168 VG-201 - Drug Profile 175 VM-902A - Drug Profile 176 VX-150 - Drug Profile 177 WITH-1101 - Drug Profile 178 zoledronic acid - Drug Profile 179 Osteoarthritis Pain - Dormant Projects 182 Osteoarthritis Pain - Discontinued Products 185 Osteoarthritis Pain - Product Development Milestones 187 Featured News & Press Releases 187 Appendix 197 Methodology 197 Coverage 197 Secondary Research 197 Primary Research 197 Expert Panel Validation 197 Contact Us 197 Disclaimer 198
List of Tables
Number of Products under Development for Osteoarthritis Pain, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Osteoarthritis Pain - Pipeline by AbbVie Inc, H1 2017 Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H1 2017 Osteoarthritis Pain - Pipeline by Allergan Plc, H1 2017 Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals Inc, H1 2017 Osteoarthritis Pain - Pipeline by Antibe Therapeutics Inc, H1 2017 Osteoarthritis Pain - Pipeline by Aralez Pharmaceuticals Inc, H1 2017 Osteoarthritis Pain - Pipeline by Arena Pharmaceuticals Inc, H1 2017 Osteoarthritis Pain - Pipeline by Array BioPharma Inc, H1 2017 Osteoarthritis Pain - Pipeline by Astellas Pharma Inc, H1 2017 Osteoarthritis Pain - Pipeline by Axsome Therapeutics Inc, H1 2017 Osteoarthritis Pain - Pipeline by BELLUS Health Inc, H1 2017 Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Osteoarthritis Pain - Pipeline by Cara Therapeutics Inc, H1 2017 Osteoarthritis Pain - Pipeline by Chromocell Corp, H1 2017 Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H1 2017 Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals Inc, H1 2017 Osteoarthritis Pain - Pipeline by Eupraxia Pharmaceuticals Inc, H1 2017 Osteoarthritis Pain - Pipeline by Flexion Therapeutics Inc, H1 2017 Osteoarthritis Pain - Pipeline by Genzyme Corp, H1 2017 Osteoarthritis Pain - Pipeline by GlaxoSmithKline Plc, H1 2017 Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H1 2017 Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals LLC, H1 2017 Osteoarthritis Pain - Pipeline by Marina Biotech Inc, H1 2017 Osteoarthritis Pain - Pipeline by Medestea Research & Production SpA, H1 2017 Osteoarthritis Pain - Pipeline by MedImmune LLC, H1 2017 Osteoarthritis Pain - Pipeline by Merck & Co Inc, H1 2017 Osteoarthritis Pain - Pipeline by Nuvo Pharmaceuticals Inc, H1 2017 Osteoarthritis Pain - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Osteoarthritis Pain - Pipeline by Pfizer Inc, H1 2017 Osteoarthritis Pain - Pipeline by Phosphagenics Ltd, H1 2017 Osteoarthritis Pain - Pipeline by ProteoThera Inc, H1 2017 Osteoarthritis Pain - Pipeline by pSivida Corp, H1 2017 Osteoarthritis Pain - Pipeline by Purdue Pharma LP, H1 2017 Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 Osteoarthritis Pain - Pipeline by Rottapharm Biotech Srl, H1 2017 Osteoarthritis Pain - Pipeline by Shionogi & Co Ltd, H1 2017 Osteoarthritis Pain - Pipeline by Symic Biomedical Inc, H1 2017 Osteoarthritis Pain - Pipeline by Taiwan Liposome Company Ltd, H1 2017 Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Inc, H1 2017 Osteoarthritis Pain - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017 Osteoarthritis Pain - Dormant Projects, H1 2017 Osteoarthritis Pain - Dormant Projects, H1 2017 (Contd..1), H1 2017 Osteoarthritis Pain - Dormant Projects, H1 2017 (Contd..2), H1 2017 Osteoarthritis Pain - Discontinued Products, H1 2017 Osteoarthritis Pain - Discontinued Products, H1 2017 (Contd..1), H1 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify